Ask the average drug company CEO about rebates given to pharmacy benefit managers (PBMs), and you'll get an earful about how they aren't good for the system. But companies have continued to play along because of a lack of other options.
For many drugs with targets in the central nervous system, it may not be the neurology target that keeps the drugs from succeeding in clinical trials, but the ability of the drug to get past the blood-brain barrier in high enough concentration to be effective.
It's been more than two decades since Doxil (doxorubicin, Johnson & Johnson), a liposome-based chemotherapy, was approved by the FDA. During that time, the field has evolved from simply protecting other tissue from highly potent drugs until they get to the site of the disease to increasing targeting and bioavailability.
It's been more than two decades since Doxil (doxorubicin, Johnson & Johnson), a liposome-based chemotherapy, was approved by the FDA. During that time, the field has evolved from simply protecting other tissue from highly potent drugs until they get to the site of the disease to increasing targeting and bioavailability.
The quest to get the first drug approved to treat fragile X is heating up with three companies – Tetra Discovery Partners Inc., Zynerba Pharmaceuticals Inc. and Ovid Therapeutics Inc. – starting clinical trials this month.
Approved in late 2016, Spinraza (nusinersen) remains the only drug cleared to treat spinal muscular atrophy (SMA), but multiple companies are looking to grab a share of the blockbuster market established by Cambridge, Mass.-based Biogen Inc. and its development partner, Ionis Pharmaceuticals Inc., of Carlsbad, Calif.
Backed with an upsized $85 million series C financing, Sutrovax Inc. is looking to supplant New York-based Pfizer Inc.'s Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) as the go-to vaccine protecting against Streptococcus pneumonia infection in the $6 billion annual market.
At the World Federation of Hemophilia (WFH) 2018 World Congress, the old and new guard of companies developing hemophilia treatments presented their plans to change the market.
